EFPIA statement on the EU-Turkey WTO Case on Pharmaceuticals
EFPIA reiterates its position in favour of an open and rules-based trading system which best supports the resilience and efficiency of global pharmaceutical supply chains. The conclusions reached by the Panel ensure non-discriminatory treatment of EU pharmaceutical exports to Turkey and continued access for Turkish patients to innovative and effective medicines, irrespective of the place of their manufacturing. EFPIA will study the details of the report and we take note of the decision of the parties to resort to appeal arbitration. EFPIA Members stand ready to work closely with the Government of Turkey with a view to continue to build an ecosystem enabling innovative medicines to benefit Turkish patients and create value for the Turkish economy.